Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
Referencias
Additional references
AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. Journal of Urology 2003;170(2 Pt 1):530‐47.
Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology 1992;148(5):1549‐57; discussion 1564.
Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker‐Corkery E, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology 1995;154(5):1770‐4.
Barry MJ, Fowler FJ, Bin L, Pitts JC, Harris CJ, Mulley AG. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. Journal of Urology 1997;157(1):10‐4; discussion 14‐5.
Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, et al. AHRQ comparative effectiveness reviews. Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: a Review. Rockville (MD): Agency for Healthcare Research and Quality (US), 2016.
Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E, European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double‐blind, placebo‐ and active‐controlled clinical trial performed in Europe. European Urology 2011;59(3):342‐52.
Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. European Urology 2010;58(3):450‐6.
Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation, 2013.
Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. Journal of Urology 2006;175(4):1422‐6; discussion 1426‐7.
Cui Y, Zong H, Zhang Y. The efficacy and safety of silodosin in treating BPH: a systematic review and meta‐analysis. International Urology and Nephrology 2012;44(6):1601‐9.
Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, et al. Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta‐analysis. European Urology 2016 Oct 4 [Epub ahead of print]. [DOI: 10.1016/j.eururo.2016.09.032]
Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Djavan B, Marberger M. A meta‐analysis on the efficacy and tolerability of alpha1‐adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology 1999;36(1):1‐13.
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics of North America 2016;43(3):289‐97.
Clarivate Analytics. EndNote. Version 7.5. Clarivate Analytics, 2016.
Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, Longo N, et al. Alpha1‐blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta‐analysis of urodynamic studies. European Urology 2016;69(6):1091‐101.
Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat SF, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta‐analysis. Journal of Sexual Medicine 2014;11(6):1554‐66.
GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non‐neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology 2015;67(6):1099‐109.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Schünemann HJ, GRADE Working Group. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.) 2008;336(7651):995‐8. [DOI: 10.1136/bmj.39490.551019.BE]
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. [DOI: 10.1002/sim.1186]
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557]
Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Juliao AA, Plata M, Kazzazi A, Bostanci Y, Djavan B. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. Current Opinion in Urology 2012;22(1):34‐9.
Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group. Silodosin, a new alpha1A‐adrenoceptor‐selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo‐controlled, double‐blind study in Japanese men. BJU International 2006;98(5):1019‐24.
Keehn A, Taylor J, Lowe FC. Phytotherapy for benign prostatic hyperplasia. Curr Urology Reports 2016;17(7):53.
Kozminski MA, Wei JT, Nelson J, Kent DM. Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU International 2015;115(2):308‐16.
Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Reviews in Urology 2007;9(4):181‐90.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]
MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 2005;66(4):780‐8.
Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A‐adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. Journal of Urology 2009;181(6):2634‐40.
Martin S, Lange K, Haren MT, Taylor AW, Wittert G. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. Journal of Urology 2014;191(1):130‐7.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long‐term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine 2003;349(25):2387‐98.
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology 2011;185(5):1793‐803.
Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha‐adrenoceptor antagonists. BJU International 2005;95 Suppl 4:29‐36.
Minneman KP, Esbenshade TA. Alpha 1‐adrenergic receptor subtypes. Annual Review of Pharmacology and Toxicology 1994;34:117‐33.
Nair SM, Pimentel MA, Gilling PJ. A review of laser treatment for symptomatic BPH (benign prostatic hyperplasia). Current Urology Reports 2016;17(6):45.
Netto NR, de Lima ML, Netto MR, D'Ancona CA. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology 1999;53(2):314‐6.
Novara G, Tubaro A, Sanseverino R, Spatafora S, Artibani W, Zattoni F, et al. Systematic review and meta‐analysis of randomized controlled trials evaluating silodosin in the treatment of non‐neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World Journal of Urology 2013;31(4):997‐1008.
Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology 2012;61(5):917‐25.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow‐up of non‐neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology 2013;64(1):118‐40.
Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F. Silodosin: a new subtype selective alpha‐1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opinion on Pharmacotherapy 2012;13(14):2085‐96.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roehrborn CG. Pathology of benign prostatic hyperplasia. International Journal of Impotence Research 2008;20 Suppl 3:S11‐8.
Schilit S, Benzeroual KE. Silodosin: a selective alpha1A‐adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clinical Therapeutics 2009;31(11):2489‐502.
Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology 2003;62(3 Suppl 1):24‐33.
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Seki N, Takahashi R, Yamaguchi A, Ito K, Takayama K, Nanri K, et al. Non‐inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: a multicenter, randomized, parallel‐group study. International Journal of Urology 2015;22(3):311‐6.
Wilt TJ, MacDonald R. Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clinical Interventions in Aging 2006;1(4):389‐401.
Yap TL, Brown C, Cromwell DA, van der Meulen J, Emberton M. The impact of self‐management of lower urinary tract symptoms on frequency‐volume chart measures. BJU International 2009;104(8):1104‐8.
Yoo TK, Cho HJ. Benign prostatic hyperplasia: from bench to clinic. Korean Journal of Urology 2012;53(3):139‐48.
Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective alpha 1A‐adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opinion on Investigational Drugs 2007;16(12):1955‐65.
